Member Info for Bothwell

I am not sure Jim will take it back private as easier to arrange funding for US while on public markets.

And I haven’t given up on US as the major opportunity and someone will take it forward.

All information for China approval is complete. Just waiting on announcement now.

On the latest announcement dates 16th March it mentions final dividend, is this for the year or never again?

I did ask recently and they did say they wouldn’t delist.

All understood Bignose and I agree but I trying to remain positive as as I am so far underwater and everyone can see we aren’t and weren’t too far away from approval in the US and China which is very annoying. Could they be waiting to take the company private then selling out could be the answer. They have taken our money to assist the process and we will be left with zero.

And we are worth £22million when we were worth over a £100million. We still have the same products and still no China and US approval yet, once we do then we must see some kind of rerate.

Lack of FDA Approval: There are currently no FDA-approved medications for PE in the US, leading to high reliance on off-label prescriptions.

Oral therapies hold the largest share—around 42% in 2024—driven by patient convenience and physician familiarity. That said, topical agents are picking up pace, especially among younger users accessing care through telehealth platforms.

Some analysts anticipate FDA movement by 2027, especially if digital tracking and remote compliance tools can be linked to drug regimens.

The global premature ejaculation (PE) treatment market, valued at approximately $1.47–2.91 billion in 2024, is projected to grow significantly to over $2–$5 billion by 2030–2033,

Plethora Solutions Ltd.

Surely if we get China and US approval then you will see RP as an investment again…

Not to worry it was just a bit on the side waiting for the transformational news from China and the US. It’s only money. Wasted everyday on food and taxes.

Founder Alex Zhavoronkov (Chief Longevity Advisor)

Point is will he use Deep Longevityto help Insilico Medicine.

Https://www.thestandard.com.hk/people/article/326151/Living-longer-is-possible-with-AI-drug-discovery

4

Deep Longevity

Deep Longevity is a small, specialized AI-driven health tech company, usually employing roughly 10-50 people, acquired by Endurance RP in 2020. Key personnel include CEO Deepankar Nayak, founder Alex Zhavoronkov (Chief Longevity Advisor),

I do know we will get China approval but how soon is the question. I agree about production but I do think that after approval in China they must be bumping up production.

Surely the money from China approval and first sale will keep keep us going.

Yes and we now have a market cap of £25 million.

Anyones guess, but all LT shareholders are in the same boat. Bignose

I don’t agree the dilution was the only way forward and it hit us all really badly.

Let’s hope there is a positive way out with China, US and now DL.

As I have eluded to Bignose the spike would now need to go from 1 HKD to 10HKD for me to breakeven after the dilutions which I am not happy about. Will it happen in the next 5 years?!

Alquemie you should have asked for a position at Regent!

623 of stock here to buy!

https://farmacianovadamaia.pt/en/cart?action=show

So it doesn’t matter if we get approval in China or the US then as you think we are waisting our time waiting for sales. Our investment is long gone then. The move to HK exchange never helped and the share dilution killed us all. As I said before we probably all been break even but all 90% down.